Cancer risk up in bilateral retinoblastoma survivors

February 23, 2012
Cancer risk up in bilateral retinoblastoma survivors
For survivors of bilateral retinoblastoma, family history is associated with an increased risk of second cancers, especially melanoma, according to a study published online Feb. 21 in the Journal of Clinical Oncology.

(HealthDay) -- For survivors of bilateral retinoblastoma (Rb), family history is associated with an increased risk of second cancers (SCs), especially melanoma, according to a study published online Feb. 21 in the Journal of Clinical Oncology.

Ruth A. Kleinerman, M.P.H., of the National Cancer Institute in Rockville, Md., and colleagues evaluated the risk of SCs in a cohort of 1,852 one-year of Rb, including 1,306 with bilateral and 816 with unilateral Rb. SCs were identified using medical records and self-report. The presence of inherited or de novo RB1 germline mutation was inferred from laterality and positive family history of Rb.

The researchers found that, after adjusting for treatment, age, and length of follow-up, there was an increased risk of SCs associated with family history of Rb for bilateral survivors (relative risk [RR], 1.37; 95 percent confidence interval [CI], 1.00 to 1.86). For survivors with a family history of Rb, there was a significantly elevated risk of (RR, 3.08; 95 percent CI, 1.23 to 7.16), but no increase in the risk for bone or soft tissue sarcoma. After adjusting for competing risk of death, 50 years after diagnosis of bilateral Rb, the cumulative incidence of SCs was significantly increased for survivors with a family history than survivors with no family history (47 versus 38 percent; P = 0.004).

"All bilateral survivors, especially those with a of Rb, and their affected family members should be alert to the risk of melanoma, especially that posed by excessive sun exposure," the authors write.

Explore further: SABCS: Loss of RB in triple negative breast cancer associated with favorable clinical outcome

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

SABCS: Loss of RB in triple negative breast cancer associated with favorable clinical outcome

December 9, 2011
Researchers at the Thomas Jefferson University Hospital and Kimmel Cancer Center at Jefferson have shown that loss of the retinoblastoma tumor suppressor gene (RB) in triple negative breast cancer patients is associated with ...

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.